<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        215-186-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LANFAST 30MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LANSOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        58.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in <strong>LANFAST </strong>is lansoprazole, which is a proton pump inhibitor. Proton pump inhibitors reduce the amount of acid that your stomach makes.</p><p>&middot;&nbsp;&nbsp; Your doctor may prescribe <strong>LANFAST </strong>for the following indications:</p><p>&middot;&nbsp;&nbsp; Treatment of duodenal and stomach ulcer</p><p>&middot;&nbsp;&nbsp; Treatment of inflammation in your oesophagus (reflux oesophagitis)</p><p>&middot;&nbsp;&nbsp; Prevention of reflux oesophagitis</p><p>&middot;&nbsp;&nbsp; Treatment of heartburn and acid regurgitation</p><p>&middot;&nbsp;&nbsp; Treatment of infections caused by the bacteria Helicobacter pylori when given in combination with antibiotic therapy</p><p>&middot;&nbsp;&nbsp; Treatment or prevention of duodenal or stomach ulcer in patients requiring continued NSAID treatment (NSAID treatment is used against pain or inflammation)</p><p>&middot;&nbsp;&nbsp; Treatment of Zollinger-Ellison syndrome.</p><p>Your doctor may have prescribed <strong>LANFAST </strong>for another indication or with a dose different from that which is written in this information leaflet. Please follow your doctor&rsquo;s instructions for taking your medicine.</p><p>You must talk to a doctor if you do not feel better or if you feel worse after 14 days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take LANFAST:</strong></p><p>if you are allergic to lansoprazole<strong> </strong>or any of the other ingredients of this medicine (listed in section 6)</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor or pharmacist before taking LANFAST.</strong></p><p>Talk to your doctor or pharmacist if you have serious liver disease. The doctor may have to adjust your dosage.</p><p>Your doctor may perform or have performed an additional investigation called an endoscopy in order to diagnose your condition and/or exclude malignant disease.</p><p>If diarrhoea occurs during the treatment with <strong>LANFAST</strong>, contact your doctor immediately, as Lansoprazole has been associated with a small increase in infectious diarrhoea.&nbsp;</p><p>If your doctor has given you <strong>LANFAST</strong> in addition to other medicines intended for the treatment of Helicobacter pylori infection (antibiotics) or together with, anti-inflammatory medicines to treat your pain or rheumatic disease: please also read the package leaflets of these medicines carefully.</p><p>Taking a proton pump inhibitor like lansoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>If you take <strong>LANFAST </strong>on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.</p><p><strong>Talk to your doctor before taking LANFAST: </strong></p><p>&middot;&nbsp;&nbsp; If you have low vitamin B<sub>12</sub> levels or have risk factors for low vitamin B<sub>12</sub> levels and receive long-term treatment with <strong>LANFAST</strong>. As with all acid reducing agents, <strong>LANFAST</strong> may lead to a reduced absorption of vitamin B<sub>12</sub>.</p><p>&middot;&nbsp;&nbsp; If you are due to have a specific blood test (Chromogranin A).</p><p>&middot;&nbsp;&nbsp; If you have ever had a skin reaction after treatment with a medicine similar to <strong>LANFAST </strong>that reduces stomach acid.</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with <strong>LANFAST</strong>. Remember to also mention any other ill-effects like pain in your joints.</p><p><strong>Other medicines and LANFAST&nbsp;&nbsp; </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular tell your doctor or pharmacist if you are taking medicines containing any of the following active substances as <strong>LANFAST </strong>may affect the way these medicines work:</p><p>&middot;&nbsp;&nbsp; HIV protease inhibitors such as atazanavir and nelfinavir (used to treat HIV)</p><p>&middot;&nbsp;&nbsp; methotrexate (used to treat autoimmune disease and cancer)</p><p>&middot;&nbsp;&nbsp; ketoconazole, itraconazole, rifampicin (used to treat infections)</p><p>&middot;&nbsp;&nbsp; digoxin (used to treat heart problems)</p><p>&middot;&nbsp;&nbsp; warfarin (used to treat blood clots)</p><p>&middot;&nbsp;&nbsp; theophylline (used to treat asthma)</p><p>&middot;&nbsp;&nbsp; tacrolimus (used to prevent transplant rejection)</p><p>&middot;&nbsp;&nbsp; fluvoxamine (used to treat depression and other psychiatric diseases)</p><p>&middot;&nbsp;&nbsp; antacids (used to treat heartburn or acid regurgitation)</p><p>&middot;&nbsp;&nbsp; sucralfate (used for healing ulcers)</p><p>&middot;&nbsp;&nbsp; St John&acute;s wort (<em>Hypericum perforatum</em>) (used to treat mild<em> </em>depression)</p><p><strong>LANFAST</strong> <strong>with food and drink</strong></p><p>For the best results from your medicine you should take <strong>LANFAST</strong> at least 30 minutes before food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Side effects such as dizziness, vertigo, tiredness and visual disturbances sometimes occur in patients taking <strong>LANFAST</strong>. If you experience side effects like these you should take caution as your ability to react may be decreased.</p><p>You alone are responsible to decide if you are in a fit condition to drive a motor vehicle or perform other tasks that demand increased concentration. Because of their effects or undesirable effects, one of the factors that can reduce your ability to do these things safely is your use of medicines. Descriptions of these effects can be found in other sections.</p><p>Read all the information in this leaflet for guidance.</p><p>Discuss with your doctor or pharmacist if you are unsure about anything.</p><p><strong>LANFAST contain sugar spheres </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow the capsule whole with a glass of water. If you find the capsules difficult to swallow your doctor may advise on alternative ways to take your medicine. Do not crush or chew these capsules or the content of an emptied capsule because this will stop them from working properly.</p><p>If you are taking <strong>LANFAST </strong>once a day, try to take them at the same time each day. You may get best results if you take <strong>LANFAST </strong>first thing in the morning.</p><p>If you are taking <strong>LANFAST&nbsp; </strong>twice a day, you should have the first dose in the morning and the second dose in the evening.</p><p>The dose of <strong>LANFAST </strong>depends on your condition. The recommended doses of <strong>LANFAST </strong>for adults are given below.</p><p>Your doctor will sometimes prescribe you a different dose and will tell you how long your treatment will last.</p><p><strong>Treatment of heartburn and acid regurgitation: </strong>one Lansoprazole<strong> </strong>15mg or one Lansoprazole<strong> </strong>30mg (one <strong>LANFAST</strong> 30mg capsule) every day for 4 weeks. If symptoms persist you should report to your doctor. If your symptoms are not relieved within 4 weeks, please contact your doctor.</p><p><strong>Treatment of duodenal ulcer: </strong>one 30mg of <strong>LANFAST </strong>capsule<strong> </strong>every day for 2 weeks</p><p><strong>Treatment of stomach ulcer: </strong>one 30mg of<strong> LANFAST</strong> capsule every day for 4 weeks</p><p><strong>Treatment of inflammation in your oesophagus (reflux oesophagitis): </strong>one 30mg of<strong> LANFAST</strong> capsule every day for 4<strong> </strong>weeks</p><p><strong>Long-term prevention of reflux oesophagitis</strong>: one Lansoprazole 15mg capsule<strong> </strong>every day, your doctor may adjust your dose to one Lansoprazole<strong> </strong>30mg capsule (one <strong>LANFAST</strong> 30mg capsule) every day.</p><p><strong>Treatment of infection of <em>Helicobacter pylori</em>: </strong>The<strong> </strong>recommended dose is one 30mg<strong> </strong>of<strong> LANFAST</strong> capsule in combination with two<strong> </strong>different antibiotics in the morning<strong> </strong>and one 30mg of<strong> LANFAST</strong> capsule in combination<strong> </strong>with two different antibiotics in the<strong> </strong>evening. Treatment will usually be<strong> </strong>every day for 7 days.<strong> </strong></p><p><u>The recommended combinations of<strong> </strong>antibiotics are:</u></p><p>&middot;&nbsp;&nbsp; 30mg <strong>LANFAST</strong> together with 250-500mg clarithromycin and 1000mg amoxicillin</p><p>&middot;&nbsp;&nbsp; 30mg <strong>LANFAST</strong> together with 250mg clarithromycin and 400- 500mg metronidazole</p><p>If you are being treated for infection because you have an ulcer, it is unlikely that your ulcer will return if the infection is successfully treated. To give your medicine the best chance of working, take it at the right time and <strong>do not miss a dose. </strong></p><p><strong>Treatment of duodenal or stomach ulcer in patients requiring continued</strong> <strong>NSAID treatment: </strong>one 30mg of<strong> LANFAST</strong> capsule every day for 4 weeks.</p><p><strong>Prevention of duodenal or stomach ulcer in patients requiring continued NSAID treatment: </strong>one Lansoprazole 15mg capsule<strong> </strong>every day, your doctor may adjust your<strong> </strong>dose to one Lansoprazole<strong> </strong>30mg capsule (one <strong>LANFAST</strong> 30mg capsule) every day.</p><p><strong>Zollinger-Ellison syndrome: </strong>The recommended dose is two 30mg of<strong> LANFAST</strong> capsules every day to start with, then depending on how you respond to <strong>LANFAST</strong>, the dose that your doctor decides is best for you.</p><p><strong>Use in children</strong></p><p><strong>LANFAST</strong> should not be given to children.</p><p><strong>If you take more LANFAST than you should</strong></p><p>If you take more <strong>LANFAST </strong>than you have been told to, seek medical advice quickly. Contact your nearest casualty department or tell your doctor or pharmacist at once.</p><p><strong>If you forget to take LANFAST&nbsp;&nbsp; </strong></p><p>If you forget to take a dose, take it as soon as your remember unless it is nearly time for your next dose. If this happens skip the missed dose and take the remaining capsules as normal. Do not take a double dose to make up for a forgotten capsule.</p><p><strong>If you stop taking LANFAST&nbsp;&nbsp; </strong></p><p>Do not stop treatment early because your symptoms have got better. Your condition may not have been fully healed and may reoccur if you do not finish your course of treatment.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you get any of the following side effects, stop taking LANFAST and tell your doctor immediately, or contact the casualty department at your nearest hospital: </strong></p><p>&middot;&nbsp;&nbsp; <strong>angioedema </strong>(symptoms may include swollen face, tongue or pharynx, difficulty to swallow, hives and difficulties to breathe)</p><p>&middot;&nbsp;&nbsp; <strong>severe hypersensitivity reactions including anaphylactic shock </strong>(symptoms may include fever, rash, swelling and sometimes a fall in blood pressure)</p><p>&middot;&nbsp;&nbsp; <strong>very severe skin reactions </strong>with reddening, blistering, severe inflammation and skin loss (Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme)</p><p>&middot;&nbsp;&nbsp; <strong>inflammation of the liver </strong>(may be seen as yellow skin or eyes).</p><p><strong>Other side effects </strong></p><p><strong>common (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp; headache, dizziness</p><p>&middot;&nbsp;&nbsp; diarrhoea, constipation, stomach pains, feeling or being sick, wind, dry or sore mouth or throat</p><p>&middot;&nbsp;&nbsp; skin rash, itching</p><p>&middot;&nbsp;&nbsp; changes in liver function test values</p><p>&middot;&nbsp;&nbsp; tiredness.</p><p>&middot;&nbsp;&nbsp; benign polyps in the stomach.</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp; joint or muscle pain</p><p>&middot;&nbsp;&nbsp; fluid retention or swelling</p><p>&middot;&nbsp;&nbsp; changes in blood cell counts</p><p>&middot;&nbsp;&nbsp; Fracture of the hip, wrist or spine (see section 2 &lsquo;Warnings and precautions&rsquo;).</p><p><strong>Rare (may affect up to 1 in 1000 people):</strong></p><p>&middot;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp; restlessness, drowsiness, confusion, hallucinations, insomnia, visual disturbances, vertigo</p><p>&middot;&nbsp;&nbsp; a change in the way things taste, loss of appetite, inflammation of your tongue (glossitis)</p><p>&middot;&nbsp;&nbsp; skin reactions such as burning or pricking feeling under the skin, bruising, reddening and excessive sweating</p><p>&middot;&nbsp;&nbsp; sensitivity to light</p><p>&middot;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp; feelings of ants creeping over the skin (paraesthesia), trembling.</p><p>&middot;&nbsp;&nbsp; anaemia (paleness)</p><p>&middot;&nbsp;&nbsp; kidney problems</p><p>&middot;&nbsp;&nbsp; pancreatitis</p><p>&middot;&nbsp;&nbsp; breast swelling in males, impotence</p><p>&middot;&nbsp;&nbsp; candidiasis (fungal infection, may affect skin or the mucosa)</p><p><strong>Very rare (may affect up to 1 in 10000 people):</strong></p><p>&middot;&nbsp;&nbsp; inflammation of your mouth (stomatitis)</p><p>&middot;&nbsp;&nbsp; colitis (bowel inflammation)</p><p>&middot;&nbsp;&nbsp; changes in test values such as sodium, cholesterol and triglyceride levels</p><p>&middot;&nbsp;&nbsp; a reduction in the number of white blood cells which may decrease your resistance to infection. If you experience an infection with symptoms such as fever and serious deterioration of your&nbsp; general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis).</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p>&middot;&nbsp;&nbsp; rash, possibly with pain in the joints.</p><p>&middot;&nbsp;&nbsp; if you are on Lansoprazole Capsules for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium</p><p>&middot;&nbsp;&nbsp; skin-related forms of lupus or a lupus rash</p><p>&middot;&nbsp;&nbsp; visual hallucinations.</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p><strong>&bull;&nbsp; Saudi Arabia:</strong></p><p><strong>&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp;&nbsp; - SFDA Call Centre: </strong>19999</p><p><strong>&nbsp;&nbsp; - E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>&nbsp;&nbsp; - Website: </strong>https://ade.sfda.gov.sa/</p><p><strong>&bull;&nbsp; Other GCC States: </strong></p><p><strong>&nbsp;&nbsp; -</strong> Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp; Do not take <strong>LANFAST </strong>after the expiry date which is stated on the the carton and blister.</p><p>-&nbsp;&nbsp; Store below 30&deg;C, in a dry place, protected from light.</p><p>-&nbsp;&nbsp; Do not take <strong>LANFAST </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lansoprazole. Each capsule contains 30mg of lansoprazole.</p><p>The other ingredients: titanium dioxide, azorubine &ndash; carmoisine, brilliant blue FCF &ndash; FD&amp;C blue 1, sugar spheres, sodium laurylsulfate, meglumine, mannitol, hypromellose 2910, macrogol 6000, talc, polysorbate 80, methacrylic acid-ethyl acrylate copolymer and gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LANFAST 30mg capsules are available in packs of 15 capsules. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                27/09/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>لانفـاسـت </strong>على المادة الفعالة لانزوبرازول، والتي تنتمي إلى مجموعة من الأدوية التي تعرف باسم مثبطات مضخة البروتون. تعمل هذه الأدوية على خفض كمية الحمض الذي تنتجه المعدة.</p><p dir="RTL">قد يصف طبيبك المعالج <strong>لانفـاسـت </strong>في الحالات المرضية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج قرحات الإثنى عشر والمعدة</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج التهاب المريء (الارتجاع المريئي)</p><p dir="RTL">&middot;&nbsp;&nbsp; للوقاية من حدوث الارتجاع المريئي</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج حرقة المعدة أو ارتجاع الحمض</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج العدوى الناجمة عن بكتيريا هيليكوباكتر بايلوري والذي يتم إعطائه بالتزامن مع العلاج بالمضادات الحيوية</p><p dir="RTL">&middot;&nbsp;&nbsp; للعلاج أو للوقاية من حدوث قرحات الإثنى عشر أو المعدة لدى المرضى الذين يتطلب منهم الاستمرار في تلقي العلاج باستخدام الأدوية غيرالستيرويدية المضادة للالتهابات (أدوية تستخدم لعلاج الألم أو الالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج متلازمة زولينجر-إليسون</p><p dir="RTL">قد يصف طبيبك المعالج<strong> لانفاست</strong> لعلاج حالات مرضية أخرى أو قد يصف جرعات مختلفة عن الجرعات المذكورة في هذه النشرة.</p><p dir="RTL">يرجى منك اتباع تعليمات طبيبك المعالج حول كيفية تناول هذا الدواء.</p><p dir="RTL">يجب عليك التحدث إلى الطبيب المعالج في حال عدم الشعور بالتحسن أو تدهور حالتك الصحية بعد مرور 14 يوماً من تلقي العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;يجب عدم تناول لانفـاسـت في الحالات التالية:</strong></p><p dir="RTL">إذا كنت تعاني من الحساسية تجاه لانزوبرازول أو تجاه أياً من المكونات الأخرى في هذا الدواء (المذكورة في البند رقم 6)</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول لانفـاسـت.</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تعاني من اضطراب خطير في الكبد. قد يقوم طبيبك المعالج بتعديل مقدار جرعة الدواء الخاصة بك.</p><p dir="RTL">قد يقوم طبيبك المعالج بإجراء فحوصات إضافية تعرف باسم فحص التنظير حتى يتمكن من تشخيص حالتك الصحية و/أو يستبعد حدوث الأمراض الخبيثة.</p><p dir="RTL">يرجى منك التواصل مع طبيبك المعالج على الفور إذا عانيت من الإسهال أثناء فترة تلقي العلاج باستخدام <strong>لانفاست</strong>، حيث صاحب تناول لانزوبرازول حدوث زيادة طفيفة لحالة الإسهال الناتج عن الإصابة بالعدوى.</p><p dir="RTL">إذا تم إعطائك <strong>لانفاست</strong> من قبل طبيبك المعالج بالإضافة إلى الأدوية الأخرى والتي تستعمل في علاج العدوى الناجمة عن بكتيريا هيليكوباكتر بايلوري (المضادات الحيوية) أو بالتزامن مع الأدوية المضادة للالتهابات التي تستخدم للحد من الألم أو لعلاج الأمراض الروماتيزمية: فيرجى منك قراءة النشرة المرفقة مع هذه الأدوية بعناية.</p><p dir="RTL">قد يؤدي تناول مثبطات مضخة البروتون على سبيل المثال لانزوبرازول إلى زيادة طفيفة لخطر الإصابة بكسور في عظمة الورك، الرسغ أو العمود الفقري، وبصفة خاصة عند تناوله لفترة زمنية أطول من سنة واحدة. يرجى منك إخبار طبيبك المعالج إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول كورتيكوستيرويدات (التي من الممكن أن تزيد من خطر الإصابة بهشاشة العظام).</p><p dir="RTL">إذا كنت تتناول <strong>لانفـاسـت</strong> لفترة طويلة الأمد (أطول من سنة واحدة) فمن المحتمل أن يقوم طبيبك المعالج بوضعك تحت إشراف طبي بشكل دوري. يجب عليك إبلاغ طبيبك المعالج عن أي أعراض جديدة أو إستثنائية .</p><p dir="RTL"><strong>يرجى منك التحدث إلى طبيبك المعالج قبل تناول لانفاست:</strong></p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من انخفاض في مستويات فيتامين ب<sub>12 </sub>أو لديك عوامل خطر الإصابة بانخفاض في مستويات فيتامين ب<sub>12 </sub>وكنت تتلقى علاج طويل الأمد باستخدام <strong>لانفاست. </strong>كما هو الحال مع جميع الأدوية التي تعمل على خفض كمية الحمض، قد يؤدي <strong>لانفاست </strong>إلى تقليل امتصاص فيتامين ب<sub>12</sub>.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت سوف تقوم بإجراء فحص دم معين (فحص كروموجرانين أ)</p><p dir="RTL">-&nbsp;&nbsp; إذا تعرضت فيما مضى إلى حدوث تفاعلات جلدية بعد تلقي العلاج باستخدام أحد الأدوية المشابهة لدواء <strong>لانفاست</strong> والتي تعمل على خفض كمية الحمض الذي تنتجه المعدة.</p><p dir="RTL">إذا تعرضت لظهور طفح جلدي لاسيما المناطق المعرضة لأشعة الشمس، يرجى منك إخبار طبيبك المعالج&nbsp; بهذا الأمر في أقرب وقت ممكن، حيث أنك قد تكون بحاجة إلى إيقاف العلاج باستخدام <strong>لانفاست</strong>. كما يجب عليك إخبار طبيبك المعالج عن أية تأثيرات غير مرغوبة بها قد تعاني منها مثل الشعور بألم في المفاصل.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع لانفـاسـت</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">وبصفة خاصة يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول الأدوية التي تحتوي على المواد الفعالة التالية حيث قد يؤثر <strong>لانفـاسـت </strong>على آلية عمل تلك الأدوية:</p><p dir="RTL">&middot; مثبطات بروتياز فيروس نقص المناعة البشرية على سبيل المثال أتازانافير ونيلفينافير (تستخدم في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot; ميثوتريكسيت (يستخدم لعلاج اضطرابات المناعة الذاتية والسرطان)</p><p dir="RTL">&middot; كيتوكونازول، إتراكونازول، ريفامبيسين (تستخدم لعلاج العدوى)</p><p dir="RTL">&middot; ديجوكسين (يستخدم لعلاج مشاكل القلب)</p><p dir="RTL">&middot; وارفارين (يستخدم لعلاج التخثرات الدموية)</p><p dir="RTL">&middot; ثيوفيلين (يستخدم لعلاج داء الربو)</p><p dir="RTL">&middot; تاكروليمس (يستخدم لمنع رفض الجسم للأعضاء المزروعة)</p><p dir="RTL">&middot; فلوفوكسامين (يستخدم لعلاج الاكتئاب والأمراض النفسية الأخرى)</p><p dir="RTL">&middot; مضادات الحموضة (تستخدم لعلاج حرقة المعدة وارتجاع الحمض)</p><p dir="RTL">&middot; سكرالفات (يستخدم لعلاج القرحات)</p><p dir="RTL">&middot; عشبة سانت جونز (عشبة العرن المثقوب) (تستخدم لعلاج الاكتئاب الطفيف)</p><p dir="RTL"><strong>لانفاست مع الطعام والشراب</strong></p><p dir="RTL">يجب عليك تناول<strong> لانفاست</strong> لمدة لا تقل عن 30 دقيقة قبل تناول وجبة الطعام للحصول على أفضل النتائج لهذا الدواء.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على المشورة الطبية قبل تناول هذا الدواء، إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك حاملاً أو تخططين لإنجاب طفلاً.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp; </strong></p><p dir="RTL">في بعض الأحيان قد تحدث تأثيرات جانبية لدى المرضى الذين يتناولون <strong>لانفـاسـت </strong>على سبيل المثال دوخة، دوار، الشعور بالتعب واضطرابات بصرية. يجب عليك توخي الحذر إذا تعرضت لمثل تلك التأثيرات الجانبية حيث قد تقل قدرتك على القيام بهذه المهام.</p><p dir="RTL">إن الشخص الذي يتناول الدواء هو الشخص الوحيد المسؤول عن تحديد ما إذا كانت لديه المقدرة على قيادة المركبات أو أداء المهام الأخرى التي تحتاج إلى زيادة في التركيز. حيث أن تناول هذا الدواء يؤدي إلى حدوث تأثيرات غير مرغوبة بها، والتي قد تقلل أحداها من قدرتك على أداء تلك المهام بأمان. تم ذكر تلك التأثيرات في قسم آخر من هذه النشرة. يجب عليك قراءة جميع المعلومات المذكورة في هذه النشرة للحصول على معلومات إرشادية.</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه في حال لم تكن متأكداً حول المعلومات التي ذكرت في هذه النشرة.</p><p dir="RTL"><strong>يحتوي لانفـاسـت على كرات السكر</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء إذا كان قد أخبرك من قبل أنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائماً تناول هذا الدواء بدقة وفقاً لتعليمات طبيبك المعالج. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه مالم تكن متأكداً من كيفية تناول هذا الدواء.</p><p dir="RTL">قم بابتلاع الكبسولة بأكملها مع كوباً من الماء. إذا وجدت صعوبة في ابتلاع الكبسولات فقد ينصحك طبيبك المعالج باستخدام طرق بديلة لتناول الدواء الخاص بك. يجب عدم سحق أو مضغ هذه الكبسولات أو ابتلاع محتوى الكبسولات المفرغة، لأن ذلك سوف يمنع عمل هذه الكبسولات بكفاءة.</p><p dir="RTL">إذا كنت تتناول <strong>لانفاست</strong> مرة واحدة يومياً، حاول تناولها في نفس الوقت يومياً. قد تحصل على أفضل النتائج إذا تناولت <strong>لانفاست</strong> يومياً في الصباح.</p><p dir="RTL">إذا كنت تتناول <strong>لانفاست</strong> مرتين يومياً، يجب تناول الجرعة الأولى في الصباح وتناول الجرعة الثانية في المساء.</p><p dir="RTL">يعتمد مقدار الجرعة من <strong>لانفاست</strong> على حالتك الصحية. مقدار الجرعة الموصى بها من <strong>لانفاست</strong> للبالغين مذكورة أدناه.</p><p dir="RTL">سوف يقوم طبيبك المعالج في بعض الأحيان بوصف جرعات مختلفة وسوف يخبرك عن المدة اللازمة التي سوف تستغرقها لتلقي العلاج.</p><p dir="RTL"><strong>علاج حرقة المعدة وارتجاع الحمض: </strong>كبسولة واحدة 15 ملغم من لانزوبرازول<strong> </strong>أو كبسولة واحدة 30 ملغم من لانزوبرازول<strong> </strong>(كبسولة واحدة<strong> </strong>30 ملغم<strong> </strong>من <strong>لانفاست</strong>) لمدة 4 أسابيع. يجب عليك إبلاغ طبيبك المعالج إذا استمرت الأعراض لديك. يرجى منك إخبار طبيبك المعالج، إذا لم تختفي الأعراض في غضون 4 أسابيع.</p><p dir="RTL"><strong>علاج قرحة الإثنى عشر: </strong>كبسولة واحدة 30 ملغم من <strong>لانفاست</strong> يومياً لمدة أسبوعين.</p><p dir="RTL"><strong>علاج قرحة المعدة: </strong>كبسولة واحدة 30 ملغم من <strong>لانفاست</strong> يومياً لمدة 4 أسابيع.&nbsp;</p><p dir="RTL"><strong>علاج الالتهاب في المريء (الارتجاع المريئي): </strong>كبسولة واحدة 30 ملغم من <strong>لانفاست</strong> يومياً لمدة 4 أسابيع.</p><p dir="RTL"><strong>العلاج طويل الأمد للوقاية من الارتجاع المريئي:</strong> كبسولة واحدة 15 ملغم من لانزوبرازول<strong> </strong>يومياً، قد يقوم طبيبك المعالج بتعديل الجرعة لتصل إلى كبسولة واحدة 30 ملغم من لانزوبرازول<strong> </strong>(كبسولة واحدة<strong> </strong>30 ملغم<strong> </strong>من <strong>لانفاست</strong>)&nbsp; يومياً.</p><p dir="RTL"><strong>علاج العدوى الناجمة عن بكتيريا هليكوباكتر بايلوري: </strong>يبلغ مقدار الجرعة الموصى بها من<strong> لانفاست </strong>كبسولة واحدة 30 ملغم بالإضافة إلى نوعين مختلفين من المضادات الحيوية في الصباح وكبسولة واحدة 30 ملغم من<strong> لانفاست</strong> بالإضافة إلى نوعين مختلفين من المضادات الحيوية في المساء. عادةً سوف يتم تلقي العلاج يومياً لمدة 7 أيام.</p><p dir="RTL"><u>المضادات الحيوية الموصى بتناولها بالتزامن مع <strong>لانفاست</strong>:</u></p><p dir="RTL">&middot; 30 ملغم من <strong>لانفاست</strong> بالتزامن مع 250 -500 ملغم من كلاريثرومايسين و1000 ملغم من أموكسيسيلين.</p><p dir="RTL">&middot; 30 ملغم من <strong>لانفاست</strong> بالتزامن مع 250 ملغم من كلاريثرومايسين و400 -500 ملغم من ميترونيدازول.</p><p dir="RTL">إذا كنت تخضع للعلاج من العدوى الناجمة عن القرحة، فمن غير المحتمل أن تعاود حدوث القرحة مرة أخرى، إذا تم علاج العدوى بطريقة ملائمة.&nbsp; يرجى منك تناول الدواء الخاص بك في موعده الصحيح <strong>وتجنب السهو عن تناول الجرعة</strong>، لكي يعمل بكفاءة عالية.</p><p dir="RTL"><strong>علاج قرحة المعدة أو الإثنى عشر للمرضى الذين تتطلب حالتهم الاستمرار في تناول الأدوية غير الستيرويدية المضادة للالتهاب: </strong>كبسولة واحدة 30 ملغم من <strong>لانفاست</strong> يومياً لمدة 4 أسابيع.</p><p dir="RTL"><strong>للوقاية من قرحة المعدة أو الإثنى عشر للمرضى الذين تتطلب حالتهم الاستمرار في تناول الأدوية غير الستيرويدية المضادة للالتهاب: </strong>كبسولة واحدة 15 ملغم من لانزوبرازول<strong> </strong>يومياً، قد يقوم طبيبك المعالج بتعديل مقدار الجرعة إلى كبسولة واحدة 30 ملغم من لانزوبرازول<strong> </strong>(كبسولة واحدة<strong> </strong>30 ملغم<strong> </strong>من <strong>لانفاست</strong>) يومياً.</p><p dir="RTL"><strong>متلازمة زولينجر اليسون</strong>: يبلغ مقدارالجرعة الابتدائية الموصى بها كبسولتان من <strong>لانفاست</strong> 30 ملغم يومياً، وبعد ذلك سوف يقرر طبيبك المعالج الجرعة الملائمة لحالتك الصحية وذلك اعتماداً على مدى استجابتك للعلاج باستخدام<strong> لانفاست</strong>.</p><p dir="RTL"><strong>تناول الدواء من قبل الأطفال</strong></p><p dir="RTL">يجب عدم إعطاء كبسولات <strong>لانفاست</strong> للأطفال.</p><p dir="RTL"><strong>إذا تناولت لانفاست بجرعة أكبر مما يجب</strong></p><p dir="RTL">إذا تناولت العديد من كبسولات <strong>لانفاست</strong> أكثر من الجرعات الموصى بها، يرجى منك طلب النصيحة الطبية على الفور. يرجى منك التوجه إلى أقرب قسم طوارئ أو إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه على الفور.</p><p dir="RTL"><strong>إذا سهوت عن تناول لانفاست</strong></p><p dir="RTL">إذا سهوت عن تناول إحدى الجرعات، فيجب عليك تناولها في أقرب وقت ممكن حال تذكرها مالم يكن قد اقترب موعد الجرعة التالية. إذا حدث ذلك تخطى عن تناول الجرعة التي قد سهوت عنها وقم بتناول الكبسولات المتبقية كالمعتاد. يجب عدم تناول جرعة مضاعفة للتعويض عن الكبسولات التي سهوت عن تناولها.</p><p dir="RTL"><strong>إذا توقفت عن تناول لانفاست</strong></p><p dir="RTL">يجب عليك عدم التوقف عن تلقي العلاج مبكراً بمجرد الشعور بتحسن حالتك الصحية. إذا لم تقم باستكمال الدورة العلاجية، فقد لا تتماثل حالتك الصحية للشفاء بصورة كاملة وقد يعاود حدوثها مرة أخرى.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يتسبب هذا الدواء في حدوث تأثيرات جانبية، على الرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>يرجى منك التوقف عن تناول لانفاست وإخبار طبيبك المعالج على الفور أو التوجه إلى قسم الحوادث في أقرب مستشفى،&nbsp; في حال حدوث أياً من التأثيرات الجانبية التالية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>وذمة وعائية</strong> (قد تتضمن الأعراض على تورم الوجه، اللسان أو البلعوم، صعوبة في البلع، طفح جلدي على شكل خلايا النحل وصعوبة في التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>تفاعلات فرط الحساسية الشديدة بما في ذلك الصدمة</strong> <strong>الاستهدافية&nbsp; </strong>(قد تتضمن الأعراض على حمى، طفح جلدي، تورم وفي بعض الأحيان انخفاض في ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>تفاعلات جلدية شديدة</strong> والمصحوبة بظهور احمرار، بثور جلدية، التهاب شديد و تقشر الجلد (متلازمة ستيفن-جونسن وانحلال البشرة السمي التنخري، حمامى متعددة الأشكال)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>التهاب في الكبد</strong> (قد يظهر على هيئة اصفرار لون الجلد أو العينين)</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى</strong></p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; صداع، دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp; إسهال، إمساك، آلام في المعدة، الشعور بالإعياء أو التوعك، ريح، جفاف أو تقرح في الفم أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيرات في قيم نتائج فحوصات وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp; أورام حميدة في المعدة</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في المفاصل أو العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp; احتباس السوائل أو حدوث تورم</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيرات في تعداد خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp; كسر في عظمة الورك، الرسغ أو العمود الفقري (انظر البند رقم 2 &laquo;تحذيرات واحتياطات&raquo;)</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp; القلق، النعاس، ارتباك، هلوسة، أرق، اضطرابات بصرية، دوار</p><p dir="RTL">&middot;&nbsp;&nbsp; تغير في طريقة تذوق الأشياء، فقدان الشهية، التهاب في اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp; تفاعلات جلدية على سبيل المثال حرقة أو الشعور بالوخز شبيه بوخز الإبر تحت الجلد، كدمات، احمرار وفرط التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp; حساسية تجاه الضوء</p><p dir="RTL">&middot;&nbsp;&nbsp; سقوط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالتنميل (الشعور بالوخز) وارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp; فقر الدم (شحوب)</p><p dir="RTL">&middot;&nbsp;&nbsp; مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب في البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp; تورم في الثدي لدى الذكور، عجز جنسي</p><p dir="RTL">&middot;&nbsp;&nbsp; داء المبيضات (العدوى الفطرية، قد تؤثر على الجلد أو الغشاء المخاطي)</p><p dir="RTL"><strong>نادرة جداً (قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب في القولون (التهاب الأمعاء)</p><p dir="RTL">&middot;&nbsp;&nbsp; تغيرات في قيم الفحوصات الطبية على سبيل المثال مستويات الصوديوم، الكوليسترول والدهون الثلاثية</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض في تعداد خلايا الدم البيضاء والمقاومة ضد العدوى. إذا عانيت من العدوى المصحوبة بظهور أعراض على سبيل المثال حمى وتدهور شديد في الصحة العامة، أو حمى مصحوبة بأعراض عدوى موضعية على سبيل المثال التهاب الحلق/البلعوم/الفم أو مشاكل في الجهاز البولي، فيجب عليك رؤية طبيبك المعالج على الفور. سوف يقوم طبيبك المعالج بإجراء فحوصات الدم للتأكد من احتمالية حدوث انخفاض في تعداد خلايا الدم البيضاء (ندرة المحببات)</p><p dir="RTL"><strong>غير معروفة (لم يتم معرفة معدل التكرار من البيانات المتاحة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي، من المحتمل أن يصاحبه ألم في المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتلقى العلاج باستخدام كبسولات لانزوبرازول<strong> </strong>لأكثر من 3 أشهر فمن المحتمل أن يحدث انخفاض في مستوى المغنيسيوم في الدم. تتضمن أعراض حدوث انخفاض في مستوى المغنيسيوم على الشعور بالتعب، انقباض العضلات اللاإرادية، ارتباك، اختلاجات، دوخة، زيادة معدل ضربات القلب. يرجى منك إخبار طبيبك المعالج على الفور، في حال حدوث أياً من هذه الأعراض. كما من الممكن أن يؤدي انخفاض مستوى المغنيسيوم إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك المعالج بإجراء فحوصات الدم بشكل دوري لمراقبة مستوى المغنيسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp; الحالات الجلدية المرتبطة بالذئبة أو الطفح الجلدي الناجم عن الذئبة.</p><p dir="RTL">&middot;&nbsp;&nbsp; هلوسة بصرية</p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong></p><p dir="RTL">في حال حدوث أياً من التأثيرات الجانبية، يرجى منك التحدث إلى طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&bull;&nbsp; المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; - مركز الاتصال الموحد: </strong>19999</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; - البريد الإلكتروني:&nbsp; </strong>npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;&nbsp;&nbsp; -<strong> الموقع الإلكتروني:</strong>&nbsp; /https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; دول الخليج العربي الأخرى: </strong></p><p dir="RTL"><strong>&nbsp; - </strong>الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp; يجب عدم تناول <strong>لانفاست</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة أو الشريط.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&deg;م، في مكان جاف، بعيداً عن الضوء.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp; يجب عدم تناول&nbsp; <strong>لانفاست</strong> إذا لاحظت علامات تلف واضحة.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد<br />بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي لانزوبرازول. تحتوي كل كبسولة على 30 ملغم من لانزوبرازول.</p><p dir="RTL">المكونات الأخرى: ثنائي أكسيد التيتانيوم، أزوربين &ndash; كارموزين، بريليانت أزرق إف سي إف &ndash; إف دي وسي الأزرق 1، كرات السكر، لوريل كبريتات الصوديوم، ميغلومين، مانيتول، هيبروميلوز 2910، ماكروغول 6000، تلك، بولي سوربات 80، حمض ميثاكريلك - إيثيل أكريليت كوبوليمر وجيلاتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر كبسولات <strong>لانفاست</strong> 30 ملغم في عبوة تحتوي على 15 كبسولة<strong>.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&quot;الخليج للصناعات الدوائية&quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             م 27/9/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lanfast 30mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains:
Item No.	Material Name	Scale (mg/Capsule)
		
	Active Ingredient:	
1.		Lansoprazole 	30.00
	Used as Lansoprazole Pellets	370.00
		
	Empty hard gelatine shell (size 1)	1 no.
1.		Titanium dioxide 	1.3143% 
2.		Azorubine – Carmoisine 	0.5143%
3.		Brilliant blue FCF – FD&C blue 1 	0.0034%
		
	Excipients for pellets	
1.		Sugar spheres (0.85 – 1.0 mm)* 	237.67
2.		Sodium lauryl sulphate **	0.02
3.		Meglumine 	1.27
4.		Mannitol 	12.55
5.		Hypromellose 2910	26.81
6.		Macrogol 6000	4.04
7.		Talc 	12.38
8.		Polysorbate 80	1.78
9.		Titanium dioxide 	4.04
10.		Methacrylic acid-ethyl acrylate copolymer 
(1:1) Dispersion 30% **	39.43
11.		Purified water ***	712.50
	
Notes: 	
*	Sugar spheres consist of: 	
		Sucrose 	80-91.5% (200.95mg)
		Maize starch 	8.5-20% (33.39mg)
		Purified water 	Max 1.5% (3.33mg)
		
**	Dry substance
***	Purified water will evaporate and will not appear in the final product.

For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatine Capsules
Description: Hard gelatine capsule, size “1”, containing white to pale brownish-white enteric coated pellets.
Colour: Cap: Maroon opaque
Body: Natural transparent
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; Treatment of duodenal and gastric ulcer</p><p>&sect; Treatment of reflux oesophagitis</p><p>&sect; Prophylaxis of reflux oesophagitis</p><p>&sect; Eradication of&nbsp;<em>Helicobacter pylori&nbsp;</em>(<em>H. pylori</em>) concurrently given with appropriate antibiotic therapy for treatment of&nbsp;<em>H.pylori</em>-associated ulcers</p><p>&sect; Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment</p><p>&sect; Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk (see section 4.2) requiring continued therapy</p><p>&sect; Symptomatic gastroesophageal reflux disease</p><p>&sect; Zollinger-Ellison syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Treatment of duodenal ulcer</strong></p><p>The recommended dose is 30 mg once daily for 2 weeks. In patients not fully healed within this time, the medication is continued at the same dose for another two weeks.</p><p><strong>Treatment of gastric ulcer</strong></p><p>The recommended dose is 30 mg once daily for 4 weeks. The ulcer usually heals within 4 weeks, but in patients not fully healed within this time, the medication may be continued at the same dose for another 4 weeks.</p><p><strong>Reflux oesophagitis</strong></p><p>The recommended dose is 30 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.</p><p><strong>Prophylaxis of reflux oesophagitis</strong></p><p>15 mg once daily. The dose may be increased up to 30 mg daily as necessary.</p><p><strong>Eradication of&nbsp;<em>Helicobacter pylori</em></strong></p><p>When selecting appropriate combination therapy consideration should be given to official local guidance regarding bacterial resistance, duration of treatment, (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.</p><p>The recommended dose is 30 mg lansoprazole twice daily for 7 days in combination with one of the following:</p><p>clarithromycin 250-500 mg twice daily + amoxicillin 1 g twice daily</p><p>clarithromycin 250 mg twice daily + metronidazole 400-500 mg twice daily</p><p><em>H. pylori&nbsp;</em>eradication rates of up to 90%, are obtained when clarithromycin is combined with lansoprazole and amoxicillin or metronidazole.</p><p>Six months after successful eradication treatment, the risk of re-infection is low and relapse is therefore unlikely.</p><p>Use of a regimen including lansoprazole 30 mg twice daily, amoxicillin 1 g twice daily and metronidazole 400-500 mg twice daily has also been examined. Lower eradication rates were seen using this combination than in regimens involving clarithromycin. It may be suitable for those who are unable to take clarithromycin as part of an eradication therapy, when local resistance rates to metronidazole are low.</p><p><strong>Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment</strong></p><p>30 mg once daily for four weeks. In patients not fully healed the treatment may be continued for another four weeks. For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/or a higher dose should probably be used.</p><p>&nbsp;</p><p><strong>Prophylaxis of NSAID associated gastric and duodenal ulcers in patients at risk (such as age &gt; 65 or history of gastric or duodenal ulcer) requiring prolonged NSAID treatment</strong></p><p>15 mg once daily. If the treatment fails the dose 30 mg once daily should be used.</p><p><strong>Symptomatic gastro-oesophageal reflux disease:</strong></p><p>The recommended dose is 15 mg or 30 mg daily. Relief of symptoms is obtained rapidly. Individual adjustment of dosage should be considered. If the symptoms are not relieved within 4 weeks with a daily dose of 30 mg, further examinations are recommended.</p><p><strong>Zollinger-Ellison syndrome</strong></p><p>The recommended initial dose is 60 mg once daily. The dose should be individually adjusted and the treatment should be continued for as long as necessary. Daily doses of up to 180 mg have been used. If the required daily dose exceeds 120 mg, it should be given in two divided doses.</p><p><strong>Renal impairment</strong></p><p>There is no need for a dose adjustment in patients with impaired renal function.</p><p><strong>Hepatic impairment</strong></p><p>Patients with moderate or severe liver disease should be kept under regular supervision and a 50% reduction of the daily dose is recommended (see section 4.4 and 5.2).</p><p><strong>Elderly</strong></p><p>Due to reduced clearance of lansoprazole in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 30 mg should not be exceeded in the elderly unless there are compelling clinical indications.</p><p><strong>Paediatric population</strong></p><p>The use of lansoprazole is not recommended in children as clinical data are limited (see section 5.2). and juvenile animal studies have findings of currently unknown human relevance (see section 5.3). &nbsp;Treatment of small children below one year of age should be avoided as available data have not shown beneficial effects in the treatment of gastro-oesophageal reflux disease.</p><p><strong><u>Method of administration</u></strong></p><p>For optimal effect, lansoprazole capsules should be taken once daily in the morning, except when used for&nbsp;<em>H. pylori&nbsp;</em>eradication when treatment should be twice a day, once in the morning and once in the evening.</p><p>Lansoprazole should be taken at least 30 minutes before food (see section 5.2). Capsules should be swallowed whole with liquid.</p><p>For patients with difficulty swallowing; studies and clinical practice suggest that the capsules may be opened and the granules mixed with a small amount of water, apple/tomato juice or sprinkled onto a small amount of soft food (e.g. yoghurt, apple puree) to ease administration. Capsules may also be opened and granules mixed with 40 ml of apple juice for administration through a nasogastric tube (see section 5.2). After preparing the suspension or mixture, the medicinal product should be administered immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In common with other anti-ulcer therapies, the possibility of malignant gastric tumour should be excluded when treating a gastric ulcer with lansoprazole because lansoprazole can mask the symptoms and delay the diagnosis.</p><p>Lansoprazole, like all proton pump inhibitors (PPIs), might increase the counts of bacteria normally present in the gastrointestinal tract. This may increase the risk of gastrointestinal infections caused by bacteria such as&nbsp;<em>Salmonella</em>,&nbsp;<em>Campylobacter</em>&nbsp;and, especially in hospitalized patients,&nbsp;<em>Clostridium difficile</em>.</p><p>Co-administration of lansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir and nelfinavir, due to significant reduction in their bioavailability (see section 4.5). If co-administration of lansoprazole with HIV protease inhibitors is unavoidable, close clinical monitoring is recommended.</p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like lansoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Lansoprazole capsules treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>Daily treatment with any acid-suppressing medications over a prolonged period of time (several years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo- or achlorhydria. Cyanocobalamin deficiency should be considered in patients with Zollinger-Ellison syndrome and other pathological hypersecretory conditions requiring long- term treatment, individuals with reduced body stores or risk factors for reduced vitamin B12 absorption (such as the elderly) on long-term therapy or if relevant clinical symptoms are observed.</p><p>Lansoprazole should be used with caution in patients with moderate and severe hepatic dysfunction (see sections 4.2 and 5.2).</p><p>Decreased gastric acidity due to lansoprazole might be expected to increase gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with lansoprazole may lead to a slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella&nbsp;</em>and&nbsp;<em>Campylobacter</em>.</p><p>In patients suffering from gastro-duodenal ulcers, the possibility of&nbsp;<em>H. pylori&nbsp;</em>infection as an etiological factor should be considered.</p><p>If lansoprazole is used in combination with antibiotics for eradication therapy of&nbsp;<em>H.pylori</em>, then the instructions for the use of these antibiotics should also be followed.</p><p>Because of limited safety data for patients on maintenance treatment for longer than 1 year, regular review of the treatment and a thorough risk/benefit assessment should regularly be performed in these patients.</p><p>Very rarely cases of colitis have been reported in patients taking lansoprazole. Therefore, in the case of severe and/or persistent diarrhoea, discontinuation of therapy should be considered.</p><p>With the exception of patients treated for the eradication of&nbsp;<em>H. pylori</em>&nbsp;infection, if diarrhoea persists, administration of lansoprazole should be discontinued, due to the possibility of microscopic colitis with thickening of the collagen bundle or infiltration of inflammatory cells noted in the large intestine submucosa. In majority of cases, symptoms of microscopic colitis resolve on discontinuation of lansoprazole.</p><p>The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID treatment should be restricted to high risk patients (e.g. previous gastrointestinal bleeding, perforation or ulcer, advanced age, concomitant use of medication known to increase the likelihood of upper GI adverse events [e.g. corticosteroids or anticoagulants], the presence of a serious co-morbidity factor or the prolonged use of NSAID maximum recommended doses).</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in the presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><strong><u>Subacute cutaneous lupus erythematosus (SCLE)</u></strong></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Lansoprazole capsules. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors (see section 4.8).</p><p><strong><u>Excipients</u></strong></p><p>&sect; <strong>Sugar spheres </strong></p><p>Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effects of lansoprazole on other medicinal products</u></strong></p><p><strong>Medicinal products with pH dependent absorption</strong></p><p>Lansoprazole may interfere with the absorption of other medicinal products where gastric pH is an important determinant of oral bioavailability.</p><p><u>HIV protease inhibitors</u></p><p>Co-administration of lansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir and nelfinavir, due to significant reduction in their bioavailability (see section 4.4).</p><p>A study has shown that co-administration of lansoprazole (60 mg once daily) with atazanavir 400 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 90% decrease in AUC and Cmax).</p><p><u>Ketoconazole and itraconazole</u></p><p>The absorption of ketoconazole and itraconazole from the gastrointestinal tract is enhanced by the presence of gastric acid. Administration of lansoprazole may result in sub-therapeutic concentrations of ketoconazole and itraconazole and the combination should be avoided.</p><p><u>Digoxin</u></p><p>Co-administration of lansoprazole and digoxin may lead to increased digoxin plasma levels. The plasma levels of digoxin should therefore be monitored and the dose of digoxin adjusted if necessary when initiating and ending lansoprazole treatment.</p><p><strong>Medicinal products metabolised by P450 enzymes</strong></p><p>Lansoprazole may increase plasma concentrations of medicinal products that are metabolised by CYP3A4. Caution is advised when combining lansoprazole with medicinal products which are metabolised by this enzyme and have a narrow therapeutic window.</p><p><u>Warfarin</u></p><p>There have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with lansoprazole and warfarin concomitantly may need to be monitored for increase in INR and prothrombin time.</p><p><u>Theophylline</u></p><p>Lansoprazole reduces the plasma concentration of theophylline, which may decrease the expected clinical effect at the dose. Patient monitoring should be taken in co-administration of lansoprazole with theophylline</p><p><u>Tacrolimus</u></p><p>Co-administration of lansoprazole increases the plasma concentrations of tacrolimus (a CYP3A and P-gp substrate). Lansoprazole exposure increased the mean exposure of tacrolimus by up to 81%.</p><p>Monitoring of tacrolimus plasma concentrations is advised when concomitant treatment with lansoprazole is initiated or ended.</p><p><strong>Medicinal products transported by P-glycoprotein</strong></p><p>Lansoprazole has been observed to inhibit the transport protein, P-glycoprotein (P-gp)&nbsp;<em>in vitro</em>. The clinical relevance of this is unknown.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Effects of other medicinal products on lansoprazole</u></strong></p><p><strong>Medicinal products which inhibit CYP2C19</strong></p><p><u>Fluvoxamine</u></p><p>A dose reduction may be considered when combining lansoprazole with the CYP2C19 inhibitor fluvoxamine. The plasma concentrations of lansoprazole increase up to 4-fold.</p><p><strong>Medicinal products which induce CYP2C19 and CYP3A4</strong></p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin, and St John&acute;s wort (<em>Hypericum perforatum</em>) can markedly reduce the plasma concentrations of lansoprazole.</p><p><strong>Others</strong></p><p><u>Methotrexate</u></p><p>Concomitant use with high-dose methotrexate may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities.</p><p><u>Sucralfate/Antacids</u></p><p>Sucralfate/Antacids may decrease the bioavailability of lansoprazole. Therefore lansoprazole should be taken at least 1 hour after taking these medicinal products.</p><p><u>Non-steroidal anti-inflammatory medicinal products</u></p><p>No clinically significant interactions of lansoprazole with nonsteroidal anti-inflammatory medicinal products have been demonstrated, although no formal interactions studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>For lansoprazole no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.</p><p>Therefore, the use of lansoprazole during pregnancy is not recommended.</p><p><strong><u>Breast-feeding</u></strong></p><p>It is not known whether lansoprazole is excreted in human breast milk. Animal studies have shown excretion of lansoprazole in milk.</p><p>A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breastfeeding for the child and the benefit of lansoprazole therapy for the woman.</p><p><strong><u>Fertility</u></strong></p><p>No human data on the effect of lansoprazole on fertility are available. Reproductive studies in pregnant rats and rabbits revealed no lansoprazole-related impairment of fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions such as dizziness, vertigo<em>,&nbsp;</em>visual disturbances and somnolence may occur (see section 4.8). Under these conditions the ability to react may be decreased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Frequencies are defined as common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>leucopenia, thrombocyto-penia, eosinophilia</p></td><td style="vertical-align:top"><p>anaemia</p></td><td style="vertical-align:top"><p>pancytopenia, agranulocytosis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>anaphylactic shock</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypomagnesaemia (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>depression</p></td><td style="vertical-align:top"><p>hallucination, insomnia, confusion</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>visual hallucinations</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache, dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>paresthesia, vertigo, restlessness, somnolence, tremor</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>visual disturbances.</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>vomiting, nausea, diarrhoea, stomach ache, constipation, flatulence, dry mouth or throat, fundic gland polyps (benign)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>pancreatitis, candidiasis of the oesophagus, glossitis, taste disturbances</p></td><td style="vertical-align:top"><p>colitis, stomatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>increase in liver enzyme levels</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hepatitis, jaundice</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>urticaria, itching, rash</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>petechiae, purpura, erythema multiforme, photosensitivity, hair loss,</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>fracture of the hip, wrist or spine (see section 4.4), arthralgia, myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>interstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>oedema</p></td><td style="vertical-align:top"><p>angioedema, fever, hyperhidrosis, anorexia, impotence</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>increase in cholesterol and triglyceride levels, hyponatremia</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of overdose on lansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instruction for treatment cannot be given. However, daily doses of up to 180 mg of lansoprazole orally and up to 90 mg of lansoprazole intravenously have been administered in trials without significant undesirable effects.</p><p>Please refer to section 4.8 for possible symptoms of lansoprazole overdose.</p><p>In the case of suspected overdose the patient should be monitored. Lansoprazole is not significantly eliminated by haemodialysis. If necessary, gastric emptying, charcoal and symptomatic therapy is recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Proton pump inhibitors, ATC code: A02BC03</p><p>Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.</p><p>Lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H+/K+ATPase causing inhibition of the enzyme activity.</p><p><strong><u>Effect on gastric acid secretion</u></strong></p><p>Lansoprazole is a specific inhibitor of the parietal cell proton pump. A single oral 30 mg dose of lansoprazole inhibits pentagastrin-stimulated gastric acid secretion by about 80%. After repeated daily administration for seven days, about 90% inhibition of gastric acid secretion is achieved. It has a corresponding effect on the basal secretion of gastric acid. A single oral dose of 30 mg reduces basal secretion by about 70%, and the patients&#39; symptoms are consequently relieved starting from the very first dose. After eight days of repeated administration the reduction is about 85%. A rapid relief of symptoms is obtained by one capsule (30 mg) daily, and most patients with duodenal ulcer recover within 2 weeks, patients with gastric ulcer and reflux oesophagitis within 4 weeks. By reducing gastric acidity, lansoprazole creates an environment in which appropriate antibiotics can be effective against&nbsp;<em>H. pylori.</em></p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lansoprazole is a racemate of two active enantiomers that are biotransformed into the active form in the acidic environment of the parietal cells. As lansoprazole is rapidly inactivated by gastric acid, it is administered orally in enteric-coated form(s) for systemic absorption.</p><p><strong><u>Absorption and distribution</u></strong></p><p>Lansoprazole exhibits high (80-90%) bioavailability with a single dose. Peak plasma levels occur within 1.5 to 2.0 hours. Intake of food slows the absorption rate of lansoprazole and reduces the bioavailability by about 50%. The plasma protein binding is 97%.</p><p>Studies have shown that granules from opened capsules give equivalent AUC as the intact capsule if the granules are suspended in a small amount of orange juice, apple juice, or tomato juice mixed with a tablespoon of apple or pear puree or sprinkled on a tablespoon of yoghurt, pudding or cottage cheese. Equivalent AUC has also been shown for granules suspended in apple juice administered through a naso-gastric tube.</p><p><strong><u>Biotransformation and elimination</u></strong></p><p>Lansoprazole is extensively metabolised by the liver and the metabolites are excreted by both the renal and biliary route. The metabolism of lansoprazole is mainly catalysed by the enzyme CYP2C19. The enzyme CYP3A4 also contributes to the metabolism. The plasma elimination half-life ranges from 1 to 2 hours following single or multiple doses in healthy subjects. There is no evidence of accumulation following multiple doses in healthy subjects. Sulphone, sulphide and 5-hydroxyl derivatives of lansoprazole have been identified in plasma. These metabolites have very little or no antisecretory activity.</p><p>A study with 14C labelled lansoprazole indicated that approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the faeces.</p><p><strong><u>Pharmacokinetics in elderly patients</u></strong></p><p>The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Peak plasma levels were not increased in the elderly.</p><p><strong><u>Pharmacokinetics in paediatric patients</u></strong></p><p>The evaluation of the pharmacokinetics in children aged 1 &ndash;17 years of age showed a similar exposure as compared to adults with doses of 15 mg for those below 30 kg of weight and 30 mg for those above.</p><p>The investigation of a dose of 17 mg/m2 body surface or 1 mg/kg body weight also resulted in comparable exposure of lansoprazole in children aged 2-3 months up to one year of age compared to adults.</p><p>Higher exposure to lansoprazole in comparison to adults has been seen in infants below the age of 2-3 months with doses of both 1.0 mg/kg and 0.5 mg/kg body weight given as a single dose.</p><p><strong><u>Pharmacokinetics in hepatic insufficiency</u></strong></p><p>The exposure of lansoprazole is doubled in patients with mild hepatic impairment and much more increased in patients with moderate and severe hepatic impairment.</p><p><strong><u>CYP2C19 poor metabolisers</u></strong></p><p>CYP2C19 is subject to genetic polymorphism and 2-6 % of the population, called poor metabolisers (PMs), are homozygote for a mutant CYP2C19 allele and therefore lacks a functional CYP2C19 enzyme. The exposure of lansoprazole is several-fold higher in PMs than in extensive metabolisers (EMs).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction or genotoxicity.</p><p>In two rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion.</p><p>Intestinal metaplasia was also observed, as were Leydig cell hyperplasia and benign Leydig cell tumours. After 18 months of treatment retinal atrophy was observed. This was not seen in monkeys, dogs or mice.</p><p>In mouse carcinogenicity studies dose-related gastric ECL cell hyperplasia developed as well as liver tumours and adenoma of rete testis.</p><p>The clinical relevance of these findings is unknown.</p><p><u>Juvenile animal studies:</u></p><p>In juvenile rats lansoprazole was administered from postnatal Day 7 (age equivalent to neonatal humans) through postnatal Day 62 (age equivalent to approximately 14 years in humans).</p><p>Studies in juvenile rats (8-week study, 6-week toxicokinetic dose titration study, developmental sensitivity study) have shown an increased incidence of cardiac valve thickening. The findings reversed or trended towards reversibility after a4-week drug free recovery period. Juvenile rats younger than postnatal Day 21 (age equivalent to approximately 2 years in humans) were more sensitive to the development of cardiac valve thickening. The safety margin to the expected human exposure is in the range of 3- to 6-fold the exposure in juvenile studies based on the AUC at the no-observed-effect level (NOEL) (8-week study, 6-week toxicokinetic dose titration study) or lowest-observed-effect level (LOEL)(developmental sensitivity study).</p><p>These studies have also shown changes in male reproductive tissue (testis and epididymis).</p><p>Moreover, growth retardation has been recorded either in males or in female rats but this led to delayed femoral growth plate thickness only in males.</p><p>The relevance of these findings to paediatric patients is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:570px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><u>Empty hard gelatine shell (size 1)</u></strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Azorubine &ndash; Carmoisine</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Brilliant blue FCF &ndash; FD&amp;C blue 1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>Excipients for pellets</u></strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Sugar spheres (0.85 &ndash; 1 mm)*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Sodium lauryl sulphate **</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Meglumine</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose 2910</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Macrogol 6000</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>7.&nbsp;&nbsp;&nbsp;&nbsp; Talc</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp; Polysorbate 80</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>9.&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>10.&nbsp; Methacrylic acid-ethyl acrylate copolymer (1:1) Dispersion 30% **</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>11.&nbsp; Purified water ***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Notes: </u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>*</p></td><td style="vertical-align:top"><p><strong>Sugar spheres consist of: </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&sect; Sucrose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&sect; Maize starch</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&sect; Purified water</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>**</p></td><td colspan="2" style="vertical-align:top"><p>Dry substance</p></td></tr><tr><td style="vertical-align:top"><p>***</p></td><td colspan="2" style="vertical-align:top"><p>Purified water will evaporate and will not appear in the final product.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, in a dry place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>15 capsules packed in a sealed - labelled bottle packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27. September. 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>